natgillin/translations-raw huggingface dataset:
A process for preparing a pharmaceutical composition in film coated tablet form as defined in any one of the preceding claims, comprising combining montelukast or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable excipient selected from at least one of diluent, disintegrant, wetting agent, lubricant, or glidant, provided that the pharmaceutically acceptable excipient is not microcrystalline cellulose. 
Postupak za pripremu farmaceutske kompozicije u obliku tablete obložene filmom prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što sadrži spajanje montelukasta ili njegove farmaceutski prihvatljive soli sa farmaceutski prihvatljivim inertnim puniteljem koji je izabran od najmanje jednog od razblaživača, sredstva za raspadanje, sredstva za vlaženje, lubrikanta ili klizajućeg sredstva uz uvjet da farmaceutski prihvatljivi inertni punitelj nije mikrokristalna celuloza.
The process of claim 16 for preparing a pharmaceutical composition as defined in claim 15 comprising blending montelukast sodium, lactose monohydrate, hydroxypropylcellulose, starch, sodium lauryl sulfate, sodium starch glycolate and magnesium stearate in a dry mixing method and compressing the blended components into tablet form. 
Postupak prema patentnom zahtjevu 16 za pripremu farmaceutske kompozicije prema patentnom zahtjevu 15, naznačen time što sadrži miješanje montelukast natrija, laktoza monohidrata, hidroksipropilceluloze, škroba, natrijevog lauril sulfata, natrijevog škrob glikolata i magnezijeva stearata u postupku suhog miješanja i prešanja izmješanih komponenti u obliku tablete.
A method as claimed in claim 11, wherein the amount of motive power so used is sufficient to overcome the energy losses arising from friction due to the rotation of the body (2) about the first axis (4). 
Postupak prema Zahtjevu 11, naznačen time, da je količina pogonske snage iskorištene na takav način dovoljna da nadoknadi gubitke energije koji su posljedica trenja pri rotacijskom kretanju tijela (2) oko prve osi (4).
A method as claimed in claim 13, wherein the vehicle is in the form of a road vehicle. 
Postupak prema Zahtjevu 13, naznačen time, da je vozilo izvedeno u obliku cestovnog vozila.
A motor (1) as claimed in claim 28 or claim 29, further comprising means for selecting a desired output torque of the motor (1) and adjusting the inclination angle (θ) in dependence on the selected output torque. 
Motor (1) prema Zahtjevu 28 ili Zahtjevu 29, naznačen time, da nadalje sadrži sredstvo za odabiranje željenog izlaznog momenta motora (1) i za prilagođavanje izlaznog kuta (θ) nagiba u zavisnosti od odabranog izlaznog momenta.
A motor (1) as claimed in claim 40, wherein the body (2) comprises a cylinder the thickness of which is tapered from a maximum value proximal to the first axis to a minimum value at its circumference. 
Motor (1) prema Zahtjevu 40, naznačen time, da tijelo (2) sadrži cilindar čija se debljina mijenja od maksimalne vrijednosti na kraju tijela bližem prvoj osi, pa do minimalne vrijednosti na svom obodu.
A motor (1) as claimed in any one of claims 20 to 41, wherein the body (2) is made from a material having a high modulus of elasticity. 
Motor (1) prema bilo kojem od Zahtjeva 20 do 41, naznačen time, da je tijelo (2) napravljeno od materijala sa visokim modulom elastičnosti.
A vehicle as claimed in claim 47 in the form of a road vehicle. 
Vozilo prema Zahtjevu 47, naznačeno time, da je izvedeno u obliku cestovnog vozila.
A vehicle as claimed in claim 47 in the form of an aircraft. 
Vozilo prema Zahtjevu 47, naznačeno time, da je izvedeno u obliku letjelice.
A vehicle as claimed in claim 47 in the form of a water-borne vehicle. 
Vozilo prema Zahtjevu 47, naznačeno time, da je izvedeno u obliku plovila.
Photovoltaic plant as in any claim hereinbefore, characterized in that said heat conductor material is charged with TiO2, graphite, SiC and Al2O3 in order to have good heat conductor characteristics. 
Fotonaponski uređaj prema bilo kojem prethodnom zahtjevu, naznačen time da se navedeni materijal koji provodi toplinu puni sa TiO2, grafitom, SiC i Al2O3 kako bi imao dobre karakteristike toplinske vodljivosti.
Photovoltaic plant as in any claim hereinbefore, characterized in that said photovoltaic means comprises a plurality of photovoltaic cells (13) assembled on a panel (11) having a layer made of solar glass (14) with an external surface (12) able to be exposed to the sun's rays. 
Fotonaponski uređaj prema bilo kojem prethodnom zahtjevu, naznačen time da navedeni fotoelektrični elementi sadrže veći broj fotoelektričnih ćelija (13) posloženih na ploču (11) koja ima sloj izrađen od solarnog stakla (14) sa vanjskom površinom (12) koja može biti izložena sunčevim zrakama.
Photovoltaic plant as in claim 6, characterized in that a fourth layer (27), made with a polyvinyl fluoride based film, is disposed on said third layer (26). 
Fotonaponski uređaj prema zahtjevu 6, naznačen time da se četvrti sloj (27), izrađen od filma na bazi polivinil fluorida, nalazi na navedenom trećem sloju (26).
Photovoltaic plant as in claim 8, characterized in that said heat exchanger (15) comprises a plurality of metal tubes (30, 35) which adhere to the metal sheet made of aluminum or stainless steel (41) by means of a heat conductive epoxy resin (31), and in which a thermovector fluid is able to flow. 
Fotonaponski uređaj prema zahtjevu 6, naznačen time da navedeni izmjenjivač topline (15) sadrži veći broj metalnih cijevi (30, 35) koje pomoću termo vodljive epoksi smole (31), prianjaju uz metalni lim izrađen od aluminija ili nehrđajućeg čelika (41), te kroz koje može strujati termovektorski fluid.
Photovoltaic plant as in claim 9, characterized in that said metal tubes (35) have a circular cross section and are accommodated in a structure (36), made of aluminum or stainless steel, which determines heat conduction with the external surface of the corresponding metal tube (35) through a heat conductive epoxy resin located in the interstices: 
Fotonaponski uređaj prema zahtjevu 9, naznačen time da navedene metalne cijevi (35) imaju kružni presjek i da su smještene na dijelu (36), izrađenom od aluminija ili nehrđajućeg čelika, koji određuje provođenje topline sa vanjskom površinom odgovarajuće metalne cijevi (35) putem termo vodljive epoksi smole smještene u međuprostorima.
Photovoltaic plant as in claim 13 or 14, characterized in that said polymer material is made conductive with graphite, carbon fibers, TiO2, Al2O3, SiC. 
Fotonaponski uređaj prema zahtjevima 13 ili 14, naznačen time da je navedeni polimerni materijal izrađen kao provodljiv korištenjem grafita, ugljičnih vlakana, TiO2, Al2O3 i SiC.
Photovoltaic plant as in any claim from 8 to 16, characterized in that said heat exchanger (15) comprises an inlet pipe (20) through which a thermovector fluid is introduced, and an exit pipe (21) through which said thermovector fluid exits after having effected a heat exchange with said photovoltaic means (11). 
Fotonaponski uređaj prema bilo kojem zahtjevu od 8 do 16, naznačen time da se navedeni izmjenjivač topline (15) sastoji od ulazne cijevi (20) kroz koju se uvodi termovektorski fluid, te izlazne cijevi (21) kroz koju navedeni termovektorski fluid izlazi nakon što je izvršio izmjenu topline sa navedenim fotonaponskim elementima (11).
The use according to claim 3 wherein the pain syndrome is a neuropathic pain syndrome. 
Upotreba u skladu s patentnim zahtjevom 3, naznačena time što bolni sindrom je sindrom neuropatske boli.
The use according to claim 4 wherein the neuropathic pain syndrome includes: diabetic neuropathy, sciatica, nonspecific lower back pain, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, neuralgia such as post-herpetic neuralgia and trigeminal neuralgia, and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions, spinal cord, nerve root, peripheral nerve and central pain pathways compressions. 
Upotreba u skladu s patentnim zahtjevom 4, naznačena time što sindrom neuropatske boli uključuje: dijabetičnu neuropatiju, išijas, nespecifičnu bol u donjem dijelu leđa, bol kod multiple skleroze, fibromialgiju, neuropatiju povezanu s HIV-om, neuralgiju, poput postherpetične neuralgije i trigeminalne neuralgije, te bol zbog fizičke traume, amputacije, raka, toksina ili kroničnih upalnih stanja, nagnječenja kralježnične moždine, korijena živca, perifernih živaca i središnjeh puteva boli.
The use according to claim 3 wherein the pain syndrome is a chronic pain. 
Upotreba u skladu s patentnim zahtjevom 3, naznačena time što bolni sindrom je kronična bol.
The use according to claim 6 wherein the chronic pain includes: chronic pain caused by inflammation, ostheoarthritis, rheumatoid arthritis or as sequela to disease, acute injury or trauma, upper back pain or lower back pain such as resulting from systematic, regional or primary spine disease, such as radiculopathy, bone pain such as due to osteoarthritis, osteoporosis, bone metastasis or unknown reasons, pelvic pain, spinal cord injury-associated pain, cardiac chest pain, non-cardiac chest pain, central post-stroke pain, myofascial pain, cancer pain, AIDS pain, sickle cell pain, geriatric pain or pain caused by headache, temporomandibular joint syndrome, gout, fibrosis or thoracic outlet syndromes, pain related to surgery and sequaelae of surgery. 
Upotreba u skladu s patentnim zahtjevom 6, naznačena time što kronična bol uključuje: kroničnu bol uzrokovanu upalom, osteoartritisom, reumatoidnim artritisom ili kao posljedicu bolesti, akutne ozljede ili traume, bol u gornjem dijelu leđa ili bol u donjem dijelu leđa, poput boli zbog sistemne, regionalne ili primarne bolesti kralježnice, poput radikulopatije, kostobolje, primjerice zbog osteoartritisa, osteoporoze, metastaza u kostima ili nepoznatog uzrika, bol u zdjelici, bol zbog ozljede kralježnične moždine, bol u prsištu zbog srca, bol u prsištu nevezana za srce, središnju bol nakon inzulta, miofascijalnu bol, bol kod raka, bol kod AIDS-a, bol kod srpaste anemije, bol kod starijih osoba ili bol kod glavobolje, sindroma temporomandibularnog zgloba, gihta, fibroze ili sindroma torakalnih otvora, bol uzrokovanu kirurškim zahvatom i posljedice kirurškog zahvata.
The use according to claim 3 wherein the pain syndrome is an acute pain. 
Upotreba u skladu s patentnim zahtjevom 3, naznačena time što bolni sindrom je akutna bol.
The use according to claim 8 wherein the acute pain includes: acute pain caused by acute injury, illness, sport-medicine injuries, carpal tunnel syndrome, burns, musculoskeletal sprains and strains, musculotendinous strain, cervicobrachial pain syndromes, gastric ulcer, duodenal ulcer, dysmenorrhea, endometriosis or surgery (such as open heart or bypass surgery), post operative pain, kidney stone pain, gallbladder pain, gallstone pain, obstetric pain or dental pain. 
Upotreba u skladu s patentnim zahtjevom 8, naznačena time što akutna bol uključuje: akutnu bol uzrokovanu akutnom ozljedom, bolesti, sportskim ozljedama, sindromom karpalnog tunela, opeklinama, muskuloskeletalnim iščašenjima i nategnućima, muskulotendinoznim nategnućem, cervikobrahijalnim bolnim sindromiom, želučanim vrijedom, vrijedom na dvanaesniku, dismenorejom, endometriozom ili kirurškim zahvatom (poput kirurškog zahvata na otvorenom srcu ili s premosnicama), postoperativnu bol, bol zbog bubrežnih kamenaca, bol žučnog mjehura, bol kod žučnih kamenaca, bol kod poroda ili zubobolju.
The use according to claim 11 wherein migraine includes: transformed migraine or evolutive headache, cluster headache, tension headache as well as secondary headache disorders such as the ones derived from infections, metabolic disorders or other systemic illnesses and other acute headaches, paroxysmal hemicrania resulting from a worsening of the above mentioned primary and secondary headaches. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što migrena uključuje: transformoranu migrenu ili evolutivnu glavobolju, klaster glavobolju, tenzijsku glavobolju, kao i poremećaje sa sekundarnom glavoboljom, poput onih uzrokovanih infekcijama, metaboličkim poremećajima ili drugim sistemnim bolestima i druge akutne glavobolje, paroksizmalnu hemikaniju do koje dolazi zbog pogoršanja gore navedene primarne i sekundarne glavobolje.
The use according to claim 1 wherein the pathological affection is selected from ankylosing spondylitis, cervical arthritis, fibromyalgia, gout, juvenile rheumatoid arthritis, lumbosacral arthritis, osteoarthritis, osteoporosis, psoriatic arthritis and rheumatic disease. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što patološko stanje se bira između ankilozantnog spondilitisa, cervikalnog artritisa, fibromialgije, gihta, juvenilnog reumatoidnog artritisa, lumbosakralnog artritisa, osteoartritisa, osteoporoze, psorijatičnog artritisa i reumatske bolesti.
The use according to any of claims 1 and 2 wherein the pathological affection is selected from ulcerative colitis, Crohn's disease, ileitis, proctitis, celiac disease, enteropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, pouchitis resulting after proctocolectomy and post ileonatal anastomosis, irritable bowel syndrome including pylorospasm, nervous indigestion, spastic colon, spastic colitis, spastic bowel, intestinal neurosis, functional colitis, mucous colitis and laxative colitis, atrophic gastritis, gastritis varialoforme, peptic ulceration, pyrosis, damage to the GI tract by Helicobacter pylori, gastroesophageal reflux disease, gastroparesis such as diabetic gastroparesis, non-ulcerative dyspepsia (NUD), emesis, diarrhea and visceral inflammation. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 i 2, naznačena time što patološko stanje se bira između ulceroznog kolitisa, Crohnove bolesti, ileitisa, proktitisa, celijakije, enteropatija, mikroskopskog ili kolagenoznog kolitisa, eozinofilnog gastroenteritisa, upale ileoanalne anastomoze nakon proktokolektomije i nakon ileonatalne anastomoze, sindroma iritabilnih crijeva, uključujući pilorospazam, neurotičnu indigestiju, spastični kolon, spastični kolitis, spastična crijeva, intestinalnu neurozu, funkcionalnog kolitisa, mukoznog kolitisa i laksativnog kolitisa, atrofičnog gastritisa, varijaloformnog gastritisa, peptičnog vrijeda, piroze, oštećenja GI sustava zbog bakterije Helicobacter pylori, bolesti gastroezofagealnog refluksa, gastropareze, poput dijabetične gastropareze, neulcerozne dispepsije (NUD), povraćanja, proljeva i upale viscere.
The use according to any of claims 1 and 2 wherein the pathological affection is selected from overactive bladder, prostatitis such as chronic bacterial and chronic non-bacterial prostatitis, prostadynia, interstitial cystitis, urinary incontinence, adnexitis, pelvic inflammation, bartholinitis and vaginitis. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 i 2, naznačena time što patološko stanje se bira između hiperaktivnog mokraćnog mjehura, prostatitisa, poput kroničnog bakterijskog i kroničnog nebakterijskog prostatitisa, prostadinije, intersticijskog cistitisa, inkontinencije mokraće, adneksitisa, upale zdjelice, bartolinitisa i vaginitisa.
A compound of claim 30 for use according to any of claims 30 and 31 wherein the pathological affection is migraine as defined in claim 12. 
Spoj u skladu s patentnim zahtjevom 30, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 30 i 31, naznačen time što patološko stanje je migrena, u skladu s patentnim zahtjevom 12.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereoisomeric mixture (S,R+R,R) 
reakciju 2,2-dimetil-1,3-dioksolan-4-karbaldehida formule [image] s vinil Grignardovim reagensom, da bi se dobio spoj formule IIa u obliku dijastereoizomerne smjese (S, R+R, R) [image]
reacting the above compound of formula IIa with 2-bromo-4-fluorophenol to obtain a compound of formula IIIa in the form of diastereoisomeric mixture (S,R+R,R) 
reakciju gore navedenog spoja formule IIa sa 2-bromo-4-fluorofenolom, da bi se dobio spoj formule IIIa u obliku dijastereoizomerne smjese (S, R+R, R) [image]
and, if desired, salifying the compound of formula IA. 
i, po želji, salifikaciju spoja formule Ia.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent to obtain a compound of formula IIb in the form of diastereoisomeric mixture (R,S+S,S) 
reakciju 2,2-dimetil-1,3dioksolan-4-karbaldehida formule [image] s vinil Grignardovim reagensom, da bi se dobio spoj formule IIb u obliku dijasteroizomerne smjese (R, S+S, S) [image]
reacting the above compound of formula IIb with 2-bromo-4-fluorophenol to give a compound of formula IIIb in the form of diastereoisomeric mixture (R,S+S,S) 
reakciju gore navedenog spoja formule IIb sa 2-bromo-4-fluorofenolom, da bi dobio spoj formule IIIb u obliku dijasteroizomerne smjese (R, S+S, S) [image]
reacting the compound of the above formula IIIb with an organoborane compound of formula wherein Y is as defined in claim 1; to obtain a compound of formula IVb in the form of diastereoisomeric mixture (R,S+S,S) wherein Y is defined above; 
reakciju smjese gore navedene formule IIIb s organoboranskim spojem formule, [image] u kojoj je Y, kako je definirano u zahtjevu 1; da bi se dobio spoj formule IVb u obliku dijasteroizomerne smjese (R, S+S, S) [image] gdje je Y kako je gore definiran;
deprotecting the compound of formula Xb to give l -NBV of the above formula IB; 
skidanje zaštite sa spoja formule Xb kako bi se dobio l-NBV gore navedene formule IB;
and, if desired, salifying the compound of formula IB. 
i, po želji, salifikaciju spoja formule IB.
A process according to claims 1 to 4 wherein step a/l is carried out by reacting a compound of formula Ia or Ib with vinyl magnesium bromide or vinyl magnesium chloride to give a compound of formula IIa or IIb in the form of diastereomeric mixture. 
Proces prema zahtjevima 1 do 4, naznačen time da se korak a/l provodi reakcijom smjese formule Ia ili Ib s vinilnim magnezij bromidom ili vinil magnezij kloridom, da bi se dobio spoj formule IIa ili IIb u obliku dijasteromerne smjese.
A process according to claims 1 to 4 wherein step b/m is carried out by reacting a compound of formula IIa or IIb with 2-bromo-4-fluorophenol in the presence of a phosphine and an aza compound under Mitsunobu conditions to give a compound of formula IIIa or IIIb in the form of diastereomeric mixture. 
Postupak prema zahtjevima 1 do 4, naznačen time da se koraci b/m provode reakcijom smjese formule IIa ili IIb sa 2-bromo-4-fluorofenolom u prisutnosti fosfina i aza spoja pod uvjetima Mitsunobu, da bi se dobio spoj formule IIIa i IIIb u obliku dijasteromerne smjese.
A process according to claims I to 4 wherein step c/n is carried out by reacting a compound of formula IIIa or IIIb with 9-borabicyclo[3.3.1]nonane to give a compound of formula IVa or IVb in the form of diastereomeric mixture. 
Postupak prema zahtjevima 1 do 4, naznačen time da se koraci c/n provode reakcijom smjese formule IIIa ili IIIb s 9-borabiciklo[3.3.1]nonanom, da bi se dobio spoj formule IVa ili IVb u obliku dijasteromer smjese.
A process according to claims I to 4 wherein step d/o is carried out by reacting a compound of formula IVa or IVb with a base in the presence of a palladium catalyst under B-alkyl Suzuki conditions to give a compound of formula Va or Vb in the form of diastereomeric mixture. 
Postupak prema zahtjevima 1 do 4, naznačen time da se koraci d/o provode reakcijom smjese formule IVa ili IVb s bazom u prisutnosti katalizatora paladija pod B-alkil Suzuki uvjetima, da bi se dobio spoj formule Va ili Vb u obliku dijasteromerne smjese.
A process according to claim 10 further comprising separating a compound of formula Va or Vb in the form of diastereomeric mixture into the single diastereomer Va (S,R) or Vb (R,S) and the single diastereomer Va (R,R) or Vb (S,S). 
Postupak prema zahtjevu 10, naznačen time da se sastoji od daljnjeg razdvajanja smjese formule Va ili Vb u obliku dijasteromerne smjese, u zasebni dijasteromer Va (S, R) ili Vb (R, S) i zasebni dijasteromer Va (R, R) ili Vb (S, S).
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereoisomeric mixture (S,R+R,R) 
reakciju 2,2-dimetil-1,3dioksolan-4-karbaldehid formule [image] s vinil Grignardovim reagensom, da bi se dobio spoj formule IIa u obliku dijasteroizomerne smjese (S, R+R, R) [image]
reacting the above compound of formula IIa with 2-bromo-4-fluorophenol or 2-bromo-4-fluorophenyl acetate by means of a palladium catalysed C-C coupling reaction, to obtain a compound of formula XIa in the form of diastereoisomeric mixture (S,R+R,R) 
reakciju gore navedenog spoja formule IIa s 2-bromo-4-fluorofenolom ili 2-bromo-4-fluorofenil acetatom pomoću reakcije C-C vezivanja katalizirane paladijem, da bi se dobio spoj formule XIa u obliku dijasteroizomerne smjese (S, R+R, R) [image]
reducing the above compound of formula XIa to obtain a compound of formula Va according to claim 1 in the form of diastereoisomeric mixture (S,R+R,R) and, if desired, separating the compound of formula Va (S,R+R,R) into the single diastereomer Va (S,R) and the single diastereomer Va (R,R). A process for preparing l -NBV of formula which comprises: 
redukciju navednog spoja formule XIa, da bi se dobio spoj formule Va prema zahtjevu 1 u obliku dijasteroizomerne smjese (S, R+R, R) i, po želji, odvajanje smjese formule Va (S, R+R, R) na zaseban dijasteromer Va (S, R) i zaseban dijasteromer Va (R, R).
reacting the above compound of formula IIb with 2-bromo-4-fluorophenol or 2-bromo-4-fluorophenyl acetate by means of a palladium catalysed C-C coupling reaction, to obtain a compound of formula XIb in the form of diastereoisomeric mixture (R,S+S,S) 
reakciju gore navedenog spoja formule IIb sa 2-bromo-4-fluorofenolom ili 2-bromo-4-fluorofenil acetatom, pomoću reakcije C-C vezivanja katalizirane paladijem, da bi se dobio spoj formule XIb u obliku dijasteroizomerne smjese (R, S+S, S) [image]
reducing the above compound of formula XIb to obtain a compound of formula Vb according to claim 2 in the form of diastereoisomeric mixture (R,S+S,S) and, if desired, separating the compound of formula Vb (R,S+S,S) into the single diastereomer Vb (R,S) and the single diastereomer Vb (S,S). 
redukciju gore navedenog spoja formule XIb da bi se dobio spoj formule Vb prema zahtjevu 2 u obliku dijasteroizomer smjese (R, S+S, S) i, po želji, odvajanje smjese formule Vb (R, S+S, S) na zaseban dijasteromer Vb (R, S) i zaseban dijasteromer Vb (S, S).
A process according to claims 15 or 16 wherein step w/y is carried out by reacting a compound of formula IIa or IIb with 2-bromo-4-fluorophenol or 2-bromo-4-fluorophenyl acetate in basic conditions in the presence of a palladium catalyst under Heck C-C couplings. 
Postupak u skladu sa zahtjevima 15 ili 16, naznačen time da se koraci w/y provode reakcijom smjese formule IIa ili IIb sa 2-bromo-4-fluorofenolom ili 2-bromo-4-fluorofenil acetatom u osnovnim uvjetima, u nazočnosti paladijevog katalizatora prema CC Heckovim vezivanjem.
The sole for shoes according to claim 1, characterized in that said protective elements (18) are flat and are constituted by net elements (20), which have a larger area than said through holes (13). 
Potplat za cipele u skladu s patentnim zahtjevom 1, naznačen time, da su navedeni zaštitni elementi (18) ravni i sačinjeni od mrežastih elemenata (20), čija je površina veća od navedenih perforiranih rupa (13).
The sole for shoes according to claim 2, characterized in that said protective elements (118) are constituted by rings (123) made of plastic material which are closed at the center by net elements (120). 
Potplat za cipele u skladu s patentnim zahtjevom 2, naznačen time, da navedene zaštitne elemente (118) tvore prstenovi (123) izrađeni od plastičnog materijala koji se zatvaraju u središtu pomoću mrežastih elemenata (120).